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ABSTRACT
Multiple myeloma may be cured by myeloablative conditioning and allogeneic blood or marrow transplantation
(alloBMT), but this occurs at the expense of high transplant-related mortality. In an endeavor to reduce
procedure-related toxicity, this study retrospectively evaluated the safety, tolerability, and efficacy of T cell
depletion by counterflow centrifugal elutriation before alloBMT. Fifty-one patients with stage II (6) or III (45)
multiple myeloma received alloBMTs using T cell depletion by elutriation. Fifty-three percent (27 of 51) of
patients had primary refractory disease at the time of transplantation, 10% (5 of 51) had relapsed disease, and
4% (2 of 51) had refractory relapsed disease. The median age was 49 (range, 32 to 62) years, and the median
time from diagnosis to transplantation was 9 (range, 4 to 58) months. Patients had received a median of 1
(range, 1 to 3) regimen and 4 (range, 2 to 16) cycles of chemotherapy. In this population, transplant-related
mortality rate was 24% (12 of 51) with 2 patients dying of graft-versus-host disease (GVHD). Thirty-one of 39
evaluable patients have experienced relapse, and the probability of progression-free survival 5 years after
alloBMT alone is 16%. Sixteen patients were given donor lymphocyte infusions (DLI) at the time of relapse
(n 11) or for persistent disease 1 year after transplantation (n 5). Acute or chronic GVHD was seen in 63%
(10 of 16) of patients given DLI. Responses were seen in 8 of 16 patients (6 complete response [CR], 2 partial
response [PR]) with 6 of 8 responding patients having GVHD. Five recipients of DLI remain in a continuous
CR, ranging from 3 to 64 months in duration. Thus, like chronic myelogenous leukemia, allogeneic T cells
appear to have potent antimyeloma activity that is critical for achieving a cure. DLI-induced remissions of
multiple myeloma can be durable, even in patients with refractory multiple myeloma. Unlike chronic myelog-
enous leukemia, the antimyeloma effect of allogeneic T cells rarely occurs in the absence of clinically
significant GVHD.
© 2003 American Society for Blood and Marrow Transplantation
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INTRODUCTION
Multiple myeloma is the second most common
hematologic malignancy and has a median survival of
3 years from the time of diagnosis [1]. The use of
dose-intensiﬁed chemotherapeutic regimens with au-
tologous blood or marrow transplantation (BMT) may
increase the survival rate of patients with multiple
myeloma, but the absence of a plateau in the survival
curves of most studies suggests that it is unlikely to be
curative [2-6].
The graft-versus-tumor effect associated with al-
logeneic BMT (alloBMT) may augment tumor kill-
ing. The largest series of allogeneic transplants for
multiple myeloma has been reported by the European
Group for Blood and Marrow Transplantation. In the
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initial report, transplant-related mortality rate was
38% in a series of 266 patients who received an al-
loBMT for multiple myeloma before1994 [7,8]. Half
of these patients had chemoresistant disease. Similar
results were seen in the Seattle cohort in which trans-
plant-related mortality rate was 57% in a series of 80
patients, 70% of whom had chemoresistant disease
and 10 of whom received unrelated donor transplants.
More recent reports have included less heavily treated
patients with chemosensitive disease and have yielded
lower transplant-related mortality rates ranging from
20% to 30% [9-12]. This reduction in transplant-
related mortality rate has not translated into an im-
provement in progression-free or overall survival
rates; overall, 20% to 30% of patients who undergo
allogeneic transplants for multiple myeloma appear to
achieve long-term disease-free survival and potentially
cure [7-9,11-14].
The three most common causes of transplant-
related mortality are infections, severe end organ
damage, and GVHD. T cell depletion has been shown
to decrease the incidence, severity, and mortality rate
associated with GVHD [11,15-20]. This report sum-
marizes our experience using elutriation to T cell
deplete allografts in the 51 patients who received al-
loBMTs for multiple myeloma between 1991 and
2000, the majority of whom had refractory disease.
PATIENTS AND METHODS
All patients undergoing T cell–depleted alloBMT
for multiple myeloma (Durie Salmon stage II or III)
from HLA-identical siblings at Johns Hopkins from
July 1991 through April 2000 were included in the
analysis. Patients were eligible for BMT if they were
65 years of age. Additional eligibility requirements
included a Karnofsky performance status of at least
70% and adequate cardiac (ejection fraction 45%),
pulmonary (forced vital capacity 50%), hepatic (bil-
irubin 2 mg/dL), and renal (creatinine 2 mg/dL)
function. All patients gave informed consent for BMT
as approved by The Joint Committee on Clinical
Investigation of the Johns Hopkins Hospital and Uni-
versity.
Bone Marrow Transplantation
Preparative therapy consisted of busulfan (1
mg/kg every 6 hours for 16 doses) followed by cyclo-
phosphamide (50 mg/kg/d  4 days). Busulfan doses
were adjusted based on pharmacokinetics [21,22]. All
dosing was based on ideal body weight, unless actual
body weight was less than ideal body weight. The
allografts were T cell depleted by counterﬂow centrif-
ugal elutriation with augmentation of CD34 cells
that accompany the T cell fraction, as previously de-
scribed [15,23-25]. Supportive care, including GVHD
prophylaxis and treatment, was provided as described
previously; no signiﬁcant changes in supportive care
occurred during this study period [24-27]. Immuno-
suppression was continued through day 180 posttrans-
plant and was not discontinued early in patients who
did not achieve a complete remission. The allografts
contained a median of 3.8 (range, 1.5 to 12)  107
mononuclear cells per kilogram, 2.7 (range, 0.75 to
17) 105 CD3 T cells per kilogram, 2.6 (range, 0.26
to 5.7)  106 CD34 cells per kilogram, and 1.5
(range, 0.19 to 4.5)  105 colony-forming unit—
granulocyte macrophage (CFU-GM) per kilogram.
Graft versus host disease was evaluated using the
Keystone staging system [28].
Response Criteria
Assessment of disease response after BMT is based
on the criteria set forth in the recent consensus state-
ment [29]. Complete response (CR) is deﬁned on the
basis of a negative immunoﬁxation in both serum and
urine, maintained for a minimum of 6 weeks. Partial
response (PR) is deﬁned as a 50% decrease in serum
paraprotein and a 90% decrease in urinary light
chains or a decrease of urinary light chains to less than
200 mg every 24 hours. The response must persist for
at least 6 weeks. Response was deﬁned by the best
response seen between day 100 and one year post-
BMT to allow for continued response because others
have shown that the median time to complete remis-
sion ranges from 120 to 270 days [11,12]. Comparison
was made to the results obtained immediately pre-
transplant if chemotherapy had not been given within
6 months before transplant. If less than 6 months
elapsed between the last chemotherapy and transplant,
then the results obtained before chemotherapy were
used for comparison.
Disease status at the time of transplant was deﬁned
as follows. CR is deﬁned on the basis of a negative
immunoﬁxation in both serum and urine, with less
than 5% plasma cells on bone marrow biopsy. PR is
deﬁned as a 50% decrease in serum paraprotein and a
90% decrease in urinary light chains or a decrease of
urinary light chains to less than 200 mg every 24
hours. Primary refractory disease is deﬁned as the
failure to achieve at least a partial remission to the
initial regimen of chemotherapy (minimum of 3 cy-
cles) or progression through treatment. Refractory
relapsed disease is deﬁned as relapse after response to
initial treatment (CR or PR) without achieving at least
PR to salvage chemotherapy.
Statistical Methods
Follow-up of patient disease status and survival
rate was completed through April 2001 with a mini-
mum follow-up of 12 months after BMT. Complete
follow-up information was available on all but 2 pa-
Allogeneic T Cells: Graft-versus-Myeloma Activity
313BB&MT
tients. Survival probability was determined using stan-
dard Kaplan-Meier methods and differences tested
with the log-rank test [30]. The statistical analysis was
performed using SPSS 11.0 and SAS. Progression-free
survival was calculated from the date of transplant to
the date of disease progression or death from any
cause. Overall survival rate was calculated from the
date of diagnosis to the date of death and from the
date of transplant to the date of death. Patients with-
out evidence of progression were censored at the time
of last contact. Cox regression was used to model
prognostic factors with respect to progression-free
and overall survival rates.
Donor Lymphocyte Infusions. The use of donor lym-
phocyte infusions (DLI) for patients with multiple
myeloma who experienced relapse or had persistent
disease 1 year after alloBMT was begun in November
1995; 16 patients in this series were given DLI. Doses
of DLI ranged from 1  107 to 1.5  108 CD3 T
cells per kilogram. As part of an ECOG protocol, 6
patients received DLI. Initial T cell doses ranged from
1  107 to 5  107 CD3 T cells per kilogram for
patients manifesting only a rise in paraprotein. For
patients with evidence of frank multiple myeloma,
deﬁned as greater than 30% plasma cells or a rapidly
rising paraprotein, a dose of 1 108 CD3T cells per
kilogram was given as the initial dose. One patient had
relapsed with plasma cell leukemia and was given a
dose of 1.5  108 CD3 T cells per kilogram. For
patients who did not respond to the initial dose and
did not have GVHD, a second infusion of T cells was
given approximately 3 months after the ﬁrst infusion.
In this case, the dose of CD3 T cells per kilogram
was increased by one-half log over the initial dose for
all patients except one who received a one-log increase
as part of a clinical trial. Five patients were given
chemotherapy (3 before and 2 after DLI). The deci-
sion to administer chemotherapy was based on the
patient’s clinical condition and was given when the
multiple myeloma appeared to be progressing rapidly.
RESULTS
Patient Characteristics
Fifty-one patients received T cell–depleted allo-
BMTs from July 1991 to April 2000 at Johns Hopkins
Oncology Center. The median age at transplant was
49 (range, 32 to 62) years. There were 29 men and 22
women. At the time of transplant, 53% (27 of 51) of
patients had primary refractory disease, 33% (17 of
51) of patients were in a partial remission, whereas
10% (5 of 51) had relapsed disease, and 4% (2 of 51)
had refractory relapsed disease (Table 1). Patients had
received a median of 4 (range, 2 to 16) cycles and one
(range, 1 to 4) regimen of chemotherapy before trans-
plantation. Forty-ﬁve patients had stage III disease,
and 6 patients had stage II disease at the time of
diagnosis. Pretransplant -2 microglobulin levels
were available on 41 patients with a median of 2.31
(range, 1.0 to 47.43) mg/L. Cytogenetics were not
available.
Engraftment and Transplant-Related Toxicity
All patients engrafted with a median time to ab-
solute neutrophil count greater than 500/mm3 of 15
(range, 11 to 76) days. The median time to platelet
recovery (20,000 / mm3) was 17 (range, 5 to 185)
days. Twelve of the 51 patients (24%) had acute
GVHD; 7 (14%) of whom had grade II or higher
acute GVHD (5, grade II; 1, grade III; 1, grade IV).
Three patients had chronic GVHD, 1 limited and 2
extensive. Chronic GVHD followed acute GVHD in
2 patients and developed de novo in 1 patient. The
transplant-related mortality rate, deﬁned as death
within the ﬁrst 180 days not caused by relapse, was
24% (12 of 51); infection (5 patients) was the ma-
jor cause of death, and 2 patients died of GVHD
(Table 2).
Disease Response
Of 39 evaluable patients, there was one CR, 17
PR, and 21 patients with no response (NR) or stable
disease. Table 3 lists the responses by disease status at
the time of transplant. Thirty-one of 39 patients have
subsequently progressed (18 with NR, 13 with PR).
The median time to progression was 13 (range, 5 to
68) months (Figure 1). This interval was 16.5 (range,
6 to 60) months in patients transplanted in PR, 13
(range, 7 to 68) months for patients with primary
Table 1. Patient Characteristics
No. of Patients (n  51)
Sex
Male 29
Female 22
Age (yr) Median 49 (32–62)
Disease status
Stage at diagnosis
Stage II 6
Stage III 45
Renal failure 2
Plasma cell leukemia 1
Extramedullary plasmacytomas 7
M protein
IgG 23
IgA 14
Light chain (lambda 7, kappa 2) 9
Non-secretory 5
Disease status at transplant
Partial remission 17
Primary refractory 27
Relapsed 5
Relapsed refractory 2
Beta-2 microglobulin at transplant 2.32 (n  41)
C. A. Huff et al.
314
refractory disease, and 12 (range, 7 to 59) months for
patients with relapsed or refractory relapsed disease.
Prognostic Factors
Patients were analyzed for factors that predicted
progression-free and overall survival after transplant.
The features analyzed included age, -2 microglobu-
lin, disease status at the time of BMT, GVHD, time
between diagnosis and transplant and paraprotein
type. Univariate analysis showed that only disease sta-
tus at the time of transplant was predictive of survival
(Table 4). Patients with primary refractory or relapsed
disease (including 2 patients with refractory relapsed
disease) had a 2.7-fold (P  .01), 95% C.I (1.1, 6.6)
increased risk of mortality compared with patients
with chemosensitive disease transplanted in partial
remission.
Donor Lymphocyte Infusions
Sixteen patients were given DLI, either for persis-
tent disease one year after transplant (5 of 16) or at the
time of progression (11 of 16; Table 5). Doses of
donor lymphocytes ranged from 1  107 to 1.5 
108CD3T cells per kilogram (Table 5). Five patients
received chemotherapy with their DLI. In 3 patients,
chemotherapy was given before DLI; in 2 patients, it
was given after DLI. The chemotherapeutic regimens
used were vincristine, adriamycin, dexamethasone
(VAD) (one to 4 courses) and cyclophosphamide, 60
mg/kg, and dexamethasone, 40 mg a day (days 1-4,
9-12, 17-20). Eleven patients received no chemother-
apy with their DLI. Of these 11, 2 patients received
local radiation therapy before DLI.
After DLI, 10 of 16 patients (63%) had acute or
chronic GVHD. Seven of 16 patients (44%) had acute
GVHD (4, grade II; 1, grade III; 2, grade IV) at a
median of 8 (range, 5 to 22) weeks after DLI, and 5 of
16 patients (31%) had chronic GVHD (3, limited; 2,
extensive). In 2 patients, chronic GVHD followed
acute GVHD. GVHD was seen at all T cell dose
levels used. Two of 5 patients had GVHD at 1  107
CD3 T cells per kilogram, 4 of 8 patients at 5  107
CD3 T cells per kilogram, 2 of 4 patients at 1  108
CD3 T cells per kilogram, and 2 of 2 patients at
1.5  108 CD3 T cells per kilogram (Table 5).
Complete remissions were seen in 6 of 16 patients
treated with DLI and partial remissions in 2 of 16
patients. There have been no relapses among the pa-
tients who achieved a complete remission, although 1
patient died of acute GVHD while in complete remis-
sion. Thus, 5 of the patients remain in continuous CR
(range, 3 to 57 months after DLI) with 3 patients in
continuous CR more than 2.5 years after DLI. Re-
Table 2. Posttransplant Course
Response to transplant
Complete remission 1
Partial remission 17
No response (stable disease) 21
GVHD
Acute
Grade 1 5
Grade 2 5
Grade 3 1
Grade 4 1
Chronic
Limited 1
Extensive 2
Death
Transplant related
GVHD 2
Infection (Aspergillus - 2, CMV - 2) 5
Veno-occlusive disease 2
Acute respiratory distress syndrome 1
Hemorrhage 1
Refractory hypotension 1
Myeloma 13
Multiorgan failure (after DLI) 1
GVHD (after DLI) 1
Table 3. Response to Transplant by Disease Status at BMT
Disease Status at Time of BMT
Response to Transplant
Complete Remission (CR) Partial Remission (PR) Stable Disease/No Response
Partial remission (n  17) 1 11 3
Primary refractory (n  27) 0 6 13
Relapsed/refractory relapsed (n  7) 0 0 5
Figure 1. Kaplan-Meier curve, progression-free survival rate (ex-
cluding responses to DLI) after T cell–depleted alloBMT for mul-
tiple myeloma; 51 patients underwent transplant from 1991-2000.
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sponses were seen at all dose levels and did not appear
to correlate with the number of T cells given. Three
of 5 patients responded at 1  107 CD3 T cells per
kilogram, 4 of 8 responded at 5  107 CD3 T cells
per kilogram, 0 of 4 responded at 1  108 CD3 T
cells per kilogram, and 1 of 2 responded at 1.5  108
CD3 T cells per kilogram.
Of the 8 responding patients, 6 (5 CR, 1 PR) had
GVHD with DLI. The median time to response was
12 (range, 8 to 15) weeks. The decline in paraprotein
correlated with the onset of GVHD. Two patients (1
CR, 1 PR) responded without the development of
GVHD. The development of GVHD did not ensure
a multiple myeloma response because 4 of 8 patients
who did not respond also had signiﬁcant GVHD. Of
the 5 patients with chronic GVHD after DLI, 3 (1 PR,
2 CR) responded, and 2 remain in CR.
There did not appear to be any association be-
tween responses and the administration of chemother-
apy in the setting of DLI. Three of 5 (1 CR, 2 PR)
patients receiving chemotherapy responded to DLI (2
before, 1 after), whereas 5 of 11 (5 CR) patients
responded to DLI in the absence of chemotherapy.
Two patients who responded to DLI have subse-
quently died: one died of acute GVHD in complete
remission and the other patient (PR) relapsed 5
months after DLI with multiple plasmacytomas. This
patient was treated with local radiation therapy and
subsequently died of disease progression. One patient
was given thalidomide after a PR to DLI and did not
respond.
Eight of 16 patients did not respond to DLI. Two
patients died of disease progression before the assess-
ment of a response to DLI. Three of the 8 received
escalating doses of T cells without response: one pa-
tient died of multiorgan failure, one had acute (grade
I) and chronic GVHD without response, and one
progressed through DLI and was given VAD for pal-
Table 4. Univariate Analysis of Prognostic Factors Associated with
Overall and Progression-Free Survival
PFS
(P Value)
OS
(P Value)
Age >40 years 0.06 0.10
B2 microglobulin 0.24 0.38
Female sex 0.63 0.64
Status at BMT
Primary ref versus relapse
versus PR 0.91 0.07
Primary ref, relapse
versus PR 0.54 0.01 (1.206–10.296)
GVHD (Grade II–VI acute
or chronic) 0.93 0.32
Time to BMT 0.55 0.92
Paraprotein type (IgA) 0.37 0.77
Table 5. Donor Lymphocyte Infusions after T-cell–Depleted AlloBMT for Multiple Myeloma
Patient
UPIN Age
BMT to
Relapse
(d)
Relapse to
DLI (d)
DLI
Dose
(CD3
T cells/
kg)
GVHD
Response Status COD
Chemotherapy/
XRT
Time to
response
(wk)
Time to
GVHD
(wk)
Acute
(Grade)
Chronic
(Limited/
Extensive)
1460 36 1474 93 1e7  (II)  CR Alive CR VAD  2 (post) 12 14
2093 56 514 33 1e7  NR Deceased MOF VAD  1 (pre) 8
68 1e8  (II) NR Cytoxan  1
2104 53 354 79 1e7  (L) NR Deceased MM () 9
2162 41 196 153 1e7   PR
Alive with
MM VAD  4 (pre) 12
2602 53 336 33 5e7   NR
Alive with
MM ()
2651 62 184 22 1e8   * Deceased MM VAD  1 (post)
2657 47 342 50 5e7   NR
Alive with
MM () 13
131 1.5e8 (I)  (L) NR
2667 50 342 43 5e7   (E) CR Alive CR () 22 15
2856 53 573 85 1e7   CR Alive CR XRT (pre) 15
2937 54 367 1 5e7  (II)  (E) CR Alive CR () 8 8
3038 44 318 67 1.5e8  (III)  (L) PR Deceased MM
Cytoxan/Decadron
 1 (pre) 9 9
3104 60 491 30 1e8  (II)  NR Deceased MM () 7
3164 50 388 82 5e7   NR
Alive with
MM ()
187 1e8   NR
3191 58 261 175 1e8   * Deceased MM XRT (pre)
3207 54 401 20 5e7 (IV)  CR Alive CR () 10 5
3281 43 199 37 5e7  (IV)  CR Deceased GVHD () 9 6
*Died before assessment of response.
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liation. Of the remaining 3 patients who did not re-
spond to DLI, one had a transient cardiomyopathy
and 2 had chronic GVHD without response. Thus, 3
of the 8 nonresponders to DLI had GVHD (one in
the setting of T cell dose escalation).
Overall Survival
At the time of analysis, 27 patients had died; 12
died of conditioning regimen–related toxicity, 13 of
multiple myeloma, and 2 patients of complications
after DLI (Table 2). Median overall survival rate for
the series was 22 (range, 0 to 108) months from the
time of transplant and 30 (range, 6 to 125) months
from the time of diagnosis (Figure 2A). When strati-
ﬁed by disease status at the time of transplant, patients
with primary refractory or relapsed disease had an
overall survival rate of 32% at 3 years compared with
65% for patients transplanted in partial remission
(P  .023; Figure 2b). Overall, 13 of 51 (26%), re-
mained free of active disease, including 8 patients after
the BMT alone (1 CR, 7 PR) and 5 patients after DLI
(all in CR). Thus, 6 of 51 (12%) remained alive in CR.
DISCUSSION
Standard alloBMT is associated with a high rate of
transplant-related mortality (range, 40% to 57%) in
patients with multiple myeloma [7,8,31]. T cell deple-
tion of donor marrow appears to lower the rate of
transplant-related toxicity, particularly GVHD. The
transplant-related mortality rate in this study was 24%
(12 of 51), with just 2 deaths resulting from GVHD in
an older (median age, 49) group of patients, the ma-
jority of whom had resistant disease. Although the
majority of patients had resistant or refractory multi-
ple myeloma, most were transplanted within one year
of diagnosis and had received only one line of chemo-
therapy before transplant and, thus, may represent a
somewhat better-prognosis group than one might in-
fer for patients with resistant disease [32,33]. Yet, this
reduction in nonrelapse mortality rate was not associ-
ated with an improvement in long-term progression-
free survival because fewer than 20% of patients are
progression free 5 years after alloBMT. Thus, T cell
depletion also appeared to reduce the development of
graft-versus-tumor activity.
In this series, using the strict requirement of a
negative immunoﬁxation electrophoresis as well as
resolution of a patient’s M-protein and marrow plas-
macytosis, only 1 patient achieved a complete remis-
sion after BMT alone. The low CR rate in our series
is most likely attributable to the use of T cell–depleted
donor marrow and not the busulfan/cyclophospha-
mide preparative regimen; results similar to ours have
been reported by Alyea et al [11]. In their series, only
1 patient achieved a CR after alloBMT using T cell–
depleted donor marrow (2 maintained CRs that were
present before BMT), whereas CR rates of 40% to
50% have been reported for primarily refractory pa-
tients undergoing unmanipulated alloBMT after
busulfan/cyclophosphamide conditioning [11,31].
Thus, at least in patients with poor-risk disease, allo-
geneic T cells appear to be required for a complete
response. The importance of allogeneic T cells is
further suggested by the ﬁnding that 6 of the 16
patients in our series achieved complete remission
after the administration of DLI. Further support for
the importance of allogeneic T cells comes from stud-
ies looking at nonmyeloablative allogeneic transplants,
which utilize T replete allografts. In a series of 31
patients, including 17 patients with progressive dis-
ease, Badros et al [34] reported complete remissions in
12 of 31 patients, 6 months after a nonmyelobalative
transplant.
The results of BMT in multiple myeloma in many
ways parallel the results in chronic myelogenous leu-
Figure 2. A, Kaplan-Meier curve, overall survival rate after T-
cell–depleted alloBMT for multiple myeloma; 51 patients under-
went transplant from 1991-2000. B, Kaplan-Meier curve, overall
survival rate after T-cell–depleted alloBMT stratiﬁed by disease
status at the time of transplant; P  .023.
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kemia (CML). Although autologous BMT may offer a
modest prolongation of survival in both diseases, it is
rarely curative [3,35]. Moreover, T cell depletion of
alloBMT is associated with a high rate of relapse in
both diseases [19,20]. The majority of CML patients
who relapse after alloBMT will enter a cytogenetic
CR after DLI, and many of these patients may be
cured [36,37]. It appears that 30% to 50% of multiple
myeloma patients who relapse after alloBMT will also
respond to DLI, and the response can be durable
[38,39]. In our series, 8 of 16 patients treated with
DLI responded (6 CR and 2 PR), and 5 remain in CR.
Similar results were reported by the European Group
for Blood and Marrow Transplantation; in their re-
cent series of 27 patients who received DLI for re-
lapsed multiple myeloma after alloBMT, 14 (6 CR)
achieved a response, and 5 patients remained in re-
mission more than 30 months after DLI [38]. Alyea et
al [11] report that 6 of 11 patients with persistent
disease after T cell–depleted alloBMT achieved a CR
when they were given CD4 T cells as DLI. Thus, as
in CML, allogeneic T cells have potent antimyeloma
activity that appears to be critical for achieving cure.
However, unlike the results of DLI in CML, our data
and those from the European Group for Blood and
Marrow Transplantation suggest that a DLI-induced
response in multiple myeloma is unlikely in the ab-
sence of clinically signiﬁcant GVHD. The lack of
correlation seen between responses, GVHD, and T
cell dose of DLI in this series is likely in part related
to the small number of patients treated at each dose.
Alternative treatment approaches that circumvent
the inherent resistance of multiple myeloma cells to
cytotoxic therapy are needed. The allogeneic graft-
versus-myeloma effect is clearly one such approach
but currently appears to be inseparable from GVHD.
It has been postulated that lymphocyte subsets play
different roles in the induction of GVT activity and
GVHD. Earlier studies have suggested that selective
depletion of CD8 lymphocytes from allografts [40]
and DLI [41-43] may reduce the risk of GVHD with-
out signiﬁcantly compromising GVT activity. Thus,
one potential approach to reducing the risk of GVHD
is the selective depletion of CD8 lymphocytes from
DLI.
Nonmyeloablative alloBMT maintains the graft-
versus-myeloma activity while limiting regimen-re-
lated toxicity [34,44-46]. Like DLI, it still carries the
risk of severe GVHD. In animal models, tumor vac-
cines in conjunction with DLI can maintain the graft-
versus-tumor effect at lower doses of donor lympho-
cytes, thereby decreasing the risk of GVHD [47].
Such approaches, which induce myeloma-speciﬁc ac-
tivity, are needed to fully harness the potent allogeneic
graft-versus-myeloma effect.
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